Digging into biopharma’s big buyout areas

Developers working in oncology, conditions of the CNS and rare diseases have been the target of more than half of the biopharma sector’s buyouts in the last five years, and half the sums spent.

Beyond these therapy areas the volume of deals happening each year makes spotting more trends harder, but a closer look at cancer and rare diseases throws up some interesting insights.